Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.

Autor: Herpers B; OcellO BV, Leiden, The Netherlands.; Crown Bioscience Netherlands BV, Leiden, The Netherlands., Eppink B; Merus NV, Utrecht, The Netherlands., James MI; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain., Cortina C; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Cañellas-Socias A; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Boj SF; Hubrecht Organoid Technology (HUB), Utrecht, the Netherlands., Hernando-Momblona X; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Glodzik D; Wellcome Sanger Institute, Hinxton, UK.; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Roovers RC; Merus NV, Utrecht, The Netherlands., van de Wetering M; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.; Oncode Institute, Hubrecht Institute, Utrecht, the Netherlands., Bartelink-Clements C; Merus NV, Utrecht, The Netherlands., Zondag-van der Zande V; Merus NV, Utrecht, The Netherlands., Mateos JG; OcellO BV, Leiden, The Netherlands.; Crown Bioscience Netherlands BV, Leiden, The Netherlands., Yan K; OcellO BV, Leiden, The Netherlands.; Crown Bioscience Netherlands BV, Leiden, The Netherlands., Salinaro L; OcellO BV, Leiden, The Netherlands., Basmeleh A; Merus NV, Utrecht, The Netherlands., Fatrai S; Merus NV, Utrecht, The Netherlands., Maussang D; Merus NV, Utrecht, The Netherlands., Lammerts van Bueren JJ; Merus NV, Utrecht, The Netherlands., Chicote I; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Serna G; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Cabellos L; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain., Ramírez L; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain., Nuciforo P; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Salazar R; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain., Santos C; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain., Villanueva A; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.; Xenopat SL, Parc Cientific de Barcelona (PCB), Barcelona, Spain., Stephan-Otto Attolini C; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain., Sancho E; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBERONC, Madrid, Spain., Palmer HG; CIBERONC, Madrid, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain., Tabernero J; CIBERONC, Madrid, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain., Stratton MR; Wellcome Sanger Institute, Hinxton, UK., de Kruif J; Merus NV, Utrecht, The Netherlands., Logtenberg T; Merus NV, Utrecht, The Netherlands., Clevers H; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.; Oncode Institute, Hubrecht Institute, Utrecht, the Netherlands., Price LS; OcellO BV, Leiden, The Netherlands.; Crown Bioscience Netherlands BV, Leiden, The Netherlands., Vries RGJ; Hubrecht Organoid Technology (HUB), Utrecht, the Netherlands., Batlle E; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain. eduard.batlle@irbbarcelona.org.; CIBERONC, Madrid, Spain. eduard.batlle@irbbarcelona.org.; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain. eduard.batlle@irbbarcelona.org., Throsby M; Merus NV, Utrecht, The Netherlands. M.Throsby@merus.nl.

Publikováno v: Nature cancer [Nat Cancer] 2022 Apr; Vol. 3 (4), pp. 418-436. Date of Electronic Publication: 2022 Apr 25.